跳至主要内容
临床试验/CTRI/2013/04/003528
CTRI/2013/04/003528已完成4 期

A prospective, double blind random study to evaluate the efficacy and safety of ProGo powder to improve hemoglobin and sugar levels in elderly anaemic patients. - Nil

Spectrum Clinical Research Pvt Ltd0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Understand and voluntarily sign an informed consent form.
  • 2. Age 50 years and older.
  • 3. Able to adhere to the study visit schedule and other protocol requirements.
  • 4. Women with Hemoglobin concentration >= 10 g/dL and < 12 g/dL and men with >= 11 g/dL and < 13 g/dL.
  • 5. Situational anemia.

排除标准

  • 1. Red blood cell transfusions within the past 3 months.
  • 2. Estimated glomerular filtration rate (eGFR) of < 30 ml/min (by abbreviated MDRD).
  • 3. Use of erythropoiesis stimulating agents (ESA) in the past 3 months.
  • 4. Active infection defined as symptomatic, requiring active treatment (prophylaxis allowed) or hospitalized for > 24 hours primarily for infection within the past month.
  • 5. Uncontrolled hypertension defined as diastolic blood pressure > 100 mm Hg or systolic blood pressure > 160 mm Hg on 2 separate occasions during screening period.
  • 6. Other primary uncorrected cause for anemia including:
  • a. Known active inflammatory disease including autoimmune diseases (e.g., systemic lupus
  • erythematosis, rheumatoid arthritis, mixed connective tissue disease, sarcoidosis, bronchiolitis obliterans, vasculitis, polymyalgia rheumatica, temporal arteritis).
  • b. Chronic active infection (e.g., HIV, viral hepatitis).
  • c. Acute infection within past 3 months (pneumonia, sepsis, bacteremia, prostatitis).
  • d. Receipt of immunosuppressive therapy in the past 2 years.
  • e. Any cancer (aside from nonâ??melanoma skin cancer) in the past 2 years or on therapy for cancer.
  • 7. Elevated AST or ALT >= 2x upper limit of normal.
  • 8. Total bilirubin > 1.5 mg/dL.
  • 9. Use of any other experimental drug or therapy within 28 days of initial screening visit.
  • 10. Subjects expected to consume nonâ??steroidal anti inflammatory drugs (NSAIDs), corticosteroids,
  • methotrexate, furosemide or anticoagulants during the course of this study.
  • 11. Elevated TSH, or other signs of hypothyroid condition.
  • 12. History of cerebral vascular accident, a clinical diagnosis of angina or myocardial infarction, any coronary interventions (PCI, Bypass, Stent placement) within the prior 12 months to reduce the risk of subject requiring
  • aspirin therapy during the trial.
  • 13. Dementia defined as the inability to independently provide informed consent.
  • 14. Recent history of gastrointestinal bleed.

研究者

发起方
Spectrum Clinical Research Pvt Ltd

相似试验